Heterogeneity of brain melanocortin receptors suggested by differential ligand binding in situ.

Tatro JB, Entwistle ML

Brain research1 Jan 1994Cited by 36 (Europe PMC)

PMID8173950DOI10.1016/0006-8993(94)91434-6PepBankPUB-08173950

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In rat brain sections, the binding affinity order was NDP-MSH >= ACTH1-24 >= alpha-MSH > gamma-MSH > ACTH4-10 in all brain structures.
In plain wordsIn lab tests on rat brain sections, NDP-MSH bound at least as strongly as the other melanocortins tested in every brain structure.
Peptide
Melanotan I (afamelanotide)
Outcome
Not applicableRank order of binding affinity in brain structures
Study
ratn: not reported in source
frozen rat brain tissue sections
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
the relative order of binding affinities of melanocortins, determined in concentration-response studies, was NDP-MSH > or = ACTH1-24 > or = alpha-MSH > gamma-MSH > ACTH4-10 in all brain structures
1 context sentence(design, population, supporting numbers)
Summary · context
The abilities of various pharmacologically active native melanocortins and structural analogs, as well as other test substances, to compete with biologically active [125I]Nle4,D-Phe7-alpha-MSH ([125I]NDP-MSH) for binding to melanocortin receptors was determined, by in vitro binding and autoradiograp…
Report a problemFND-0817395004

Studies that did not test the peptide alone3

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

02LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement
In rat brain sections, alpha-MSH, des-acetyl-alpha-MSH, beta-MSH and ACTH1-24 at 1 microM virtually eliminated binding of the tracer [125I]NDP-MSH in all brain structures studied.
In plain wordsIn lab tests on rat brain sections, other melanocortin peptides almost fully blocked the binding of labelled NDP-MSH.
Peptide
Melanotan I (afamelanotide)
Outcome
DecreaseCompetition for [125I]NDP-MSH binding by native melanocortins
Study
ratn: not reported in source
frozen rat brain tissue sections
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
each of the melanocortin peptides alpha-MSH, des-acetyl-alpha-MSH, beta-MSH and ACTH1-24 when present at 1 microM virtually eliminated [125I]NDP-MSH binding in each of a series of brain structures
1 context sentence(design, population, supporting numbers)
Summary · context
The abilities of various pharmacologically active native melanocortins and structural analogs, as well as other test substances, to compete with biologically active [125I]Nle4,D-Phe7-alpha-MSH ([125I]NDP-MSH) for binding to melanocortin receptors was determined, by in vitro binding and autoradiograp…
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).
Report a problemFND-0817395001
03LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement
In rat brain sections, the analogs Org2766, ACTH4-9 and alpha-MSH11-13 did not affect [125I]NDP-MSH binding at concentrations up to 100 microM.
In plain wordsIn lab tests on rat brain sections, three other melanocortin analogs did not change the binding of labelled NDP-MSH.
Peptide
Melanotan I (afamelanotide)
Outcome
No significant changeEffect of Org2766, ACTH4-9 and alpha-MSH11-13 on [125I]NDP-MSH binding
Study
ratn: not reported in source
frozen rat brain tissue sections
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
the behaviorally and neurotrophically active melanocortin analogs Met(O2),D-Lys,Phe9-alpha-MSH4-9 (Org2766), ACTH4-9, and the antipyretic peptide alpha-MSH11-13 did not affect [125I]NDP-MSH binding at concentrations up to 100 microM
1 context sentence(design, population, supporting numbers)
Summary · context
The abilities of various pharmacologically active native melanocortins and structural analogs, as well as other test substances, to compete with biologically active [125I]Nle4,D-Phe7-alpha-MSH ([125I]NDP-MSH) for binding to melanocortin receptors was determined, by in vitro binding and autoradiograp…
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).
Report a problemFND-0817395002
04LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement
In rat brain sections, [125I]NDP-MSH binding was unaffected by ACTH1-4, ACTH34-39, VIP, acetaminophen and lysine-salicylate.
In plain wordsIn lab tests on rat brain sections, several unrelated peptides and two fever drugs did not change the binding of labelled NDP-MSH.
Peptide
Melanotan I (afamelanotide)
Outcome
No significant changeEffect of nonmelanotropic peptides and antipyretic drugs on [125I]NDP-MSH binding
Study
ratn: not reported in source
frozen rat brain tissue sections
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
Binding of [125I]NDP-MSH was also unaffected by the nonmelanotropic peptides ACTH1-4, ACTH34-39 and vasoactive intestinal polypeptide (VIP) and by the antipyretic drugs acetaminophen and lysine-salicylate.
1 context sentence(design, population, supporting numbers)
Summary · context
The abilities of various pharmacologically active native melanocortins and structural analogs, as well as other test substances, to compete with biologically active [125I]Nle4,D-Phe7-alpha-MSH ([125I]NDP-MSH) for binding to melanocortin receptors was determined, by in vitro binding and autoradiograp…
In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).
Report a problemFND-0817395003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.